New treatment plan for standardized diagnosis and treatment of blind diabetic retinopathy in perioperative period of cataract

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000029363

Enrollment

Unknown

Registered

2020-01-26

Start date

2020-02-01

Completion date

Unknown

Last updated

2020-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cataract

Interventions

Group 1:intravitreal injection of anti-VEGF drugs in cataract surgery

Group 2:intravitreal injection of glucocorticoids during cataract surgery

Group 3:intravitreal injection of anti-VEGF drugs and glucocorticoids in cataract surgery

Group 4:cataract surgery only

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. patients with type 1 or type 2 diabetes, with mild, moderate opacity of the lens, requiring cataract surgery; 2. preoperative fundus, OCT or FFA examination revealed severe blinding DR in patients; 3. preoperative fundus, OCT or FFA examination found clinically significant DME or 1. dense cataract, can not see the fundus, requiring cataract surgery; 2. patients with type 1 or type 2 diabetes have a long course of disease, poor glycemic control, diabetic complications in the anterior segment, and diabetic complications in the contralateral eye.

Exclusion criteria

Exclusion criteria: 1. active intraocular inflammation in either eye; 2. vitreous surgery may be required for severe vitreous hemorrhage or traction retinal detachment; 3. neovascular glaucoma or intractable glaucoma; 4. intraocular surgery/ any kind of intravitreal drug injection / retinal laser treatment of diabetic ME / trauma/vitreous surgery within the previous 3 months; 5. conditions (corneal scar, vitreous hemorrhage, macular anterior membrane, macular hole, congenital macular anatomy, optic neuropathy, etc.) that the investigators believed are associated with a low probability of visual acuity restoration; 6. expected poor compliance; 7. pregnancy or breastfeeding women or other diseases that may affect the results of this study, such as patients with malignant tumors; 8. any known history of adverse reactions to anti-VEGF drugs; 9. myocardial infarction, cerebrovascular accident or refractory hypertension within the previous 3 months.

Design outcomes

Primary

Measure	Time frame
central subfield thickness;best-corrected visual acuity;aqueous cytokines;	—

Countries

China

Contacts

Public ContactHuaijin Guan

Affiliated Hospital of Nantong University

sushu.sunny@aliyun.com+86 13809088972

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026